Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 644

1.

Targeting the CALR interactome in myeloproliferative neoplasms.

Pronier E, Cifani P, Merlinsky TR, Berman KB, Somasundara AVH, Rampal RK, LaCava J, Wei KE, Pastore F, Maag JL, Park J, Koche R, Kentsis A, Levine RL.

JCI Insight. 2018 Nov 15;3(22). pii: 122703. doi: 10.1172/jci.insight.122703. [Epub ahead of print]

PMID:
30429377
2.

Isoform switching as a mechanism of acquired resistance to mutant isocitrate dehydrogenase inhibition.

Harding JJ, Lowery MA, Shih AH, Schvartzman JM, Hou S, Famulare C, Patel M, Roshal M, Do RK, Zehir A, You D, Selcuklu SD, Viale A, Tallman MS, Hyman DM, Reznik E, Finley LWS, Papaemmanuil E, Tosolini A, Frattini MG, MacBeth KJ, Liu G, Fan B, Choe S, Wu B, Janjigian YY, Mellinghoff IK, Diaz LA, Levine RL, Abou-Alfa GK, Stein E, Intlekofer AM.

Cancer Discov. 2018 Oct 24. pii: CD-18-0877. doi: 10.1158/2159-8290.CD-18-0877. [Epub ahead of print]

PMID:
30355724
3.

Oxidation of Methionine 77 in Calmodulin Alters Mouse Growth and Behavior.

Marimoutou M, Springer DA, Liu C, Kim G, Levine RL.

Antioxidants (Basel). 2018 Oct 13;7(10). pii: E140. doi: 10.3390/antiox7100140.

4.

TET2 deficiency causes germinal center hyperplasia, impairs plasma cell differentiation and promotes B-cell lymphomagenesis.

Dominguez PM, Ghamlouch H, Rosikiewicz W, Kumar P, Béguelin W, Fontan L, Rivas MA, Pawlikowska P, Armand M, Mouly E, Torres-Martin M, Doane AS, Calvo Fernandez MT, Durant M, Della-Valle V, Teater M, Cimmino L, Droin N, Tadros S, Motanagh S, Shih AH, Rubin MA, Tam W, Aifantis I, Levine RL, Elemento O, Inghirami G, Green MR, Figueroa ME, Bernard OA, Aoufouchi S, Li S, Shaknovich R, Melnick AM.

Cancer Discov. 2018 Oct 1. pii: CD-18-0657. doi: 10.1158/2159-8290.CD-18-0657. [Epub ahead of print]

PMID:
30274972
5.

HOXA9 Reprograms the Enhancer Landscape to Promote Leukemogenesis.

Sun Y, Zhou B, Mao F, Xu J, Miao H, Zou Z, Phuc Khoa LT, Jang Y, Cai S, Witkin M, Koche R, Ge K, Dressler GR, Levine RL, Armstrong SA, Dou Y, Hess JL.

Cancer Cell. 2018 Oct 8;34(4):643-658.e5. doi: 10.1016/j.ccell.2018.08.018. Epub 2018 Sep 27.

PMID:
30270123
6.

JAK2/IDH-mutant-driven myeloproliferative neoplasm is sensitive to combined targeted inhibition.

McKenney AS, Lau AN, Somasundara AVH, Spitzer B, Intlekofer AM, Ahn J, Shank K, Rapaport FT, Patel MA, Papalexi E, Shih AH, Chiu A, Freinkman E, Akbay EA, Steadman M, Nagaraja R, Yen K, Teruya-Feldstein J, Wong KK, Rampal R, Vander Heiden MG, Thompson CB, Levine RL.

J Clin Invest. 2018 Oct 1;128(10):4743. doi: 10.1172/JCI124920. Epub 2018 Sep 17. No abstract available.

7.

Radioactive Iodine-Related Clonal Hematopoiesis in Thyroid Cancer Is Common and Associated With Decreased Survival.

Boucai L, Falcone J, Ukena J, Coombs CC, Zehir A, Ptashkin R, Berger MF, Levine RL, Fagin JA.

J Clin Endocrinol Metab. 2018 Nov 1;103(11):4216-4223. doi: 10.1210/jc.2018-00803.

PMID:
30137527
8.

Genetic and epigenetic evolution as a contributor to WT1-mutant leukemogenesis.

Pronier E, Bowman RL, Ahn J, Glass J, Kandoth C, Merlinsky TR, Whitfield JT, Durham BH, Gruet A, Hanasoge Somasundara AV, Rampal R, Melnick A, Koche RP, Taylor BS, Levine RL.

Blood. 2018 Sep 20;132(12):1265-1278. doi: 10.1182/blood-2018-03-837468. Epub 2018 Jul 31.

PMID:
30064973
9.

Clonal diversity predicts adverse outcome in chronic lymphocytic leukemia.

Leeksma AC, Taylor J, Wu B, Gardner JR, He J, Nahas M, Gonen M, Alemayehu WG, Te Raa D, Walther T, Hüllein J, Dietrich S, Claus R, de Boer F, de Heer K, Dubois J, Dampmann M, Dürig J, van Oers MHJ, Geisler CH, Eldering E, Levine RL, Miller V, Mughal T, Lamanna N, Frattini MG, Heaney ML, Zelenetz A, Zenz T, Abdel-Wahab O, Kater AP.

Leukemia. 2018 Jul 23. doi: 10.1038/s41375-018-0215-9. [Epub ahead of print]

PMID:
30038380
10.

An Updated History of the American Association of Gynecologic Laparoscopists (2001-2017).

Pasic RP, Levine RL.

J Minim Invasive Gynecol. 2018 Jun 25. pii: S1553-4650(18)30319-4. doi: 10.1016/j.jmig.2018.06.011. [Epub ahead of print] No abstract available.

PMID:
29953956
11.

Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations.

Intlekofer AM, Shih AH, Wang B, Nazir A, Rustenburg AS, Albanese SK, Patel M, Famulare C, Correa FM, Takemoto N, Durani V, Liu H, Taylor J, Farnoud N, Papaemmanuil E, Cross JR, Tallman MS, Arcila ME, Roshal M, Petsko GA, Wu B, Choe S, Konteatis ZD, Biller SA, Chodera JD, Thompson CB, Levine RL, Stein EM.

Nature. 2018 Jul;559(7712):125-129. doi: 10.1038/s41586-018-0251-7. Epub 2018 Jun 27.

PMID:
29950729
12.

Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay.

Intlekofer AM, Joffe E, Batlevi CL, Hilden P, He J, Seshan VE, Zelenetz AD, Palomba ML, Moskowitz CH, Portlock C, Straus DJ, Noy A, Horwitz SM, Gerecitano JF, Moskowitz A, Hamlin P, Matasar MJ, Kumar A, van den Brink MR, Knapp KM, Pichardo JD, Nahas MK, Trabucco SE, Mughal T, Copeland AR, Papaemmanuil E, Moarii M, Levine RL, Dogan A, Miller VA, Younes A.

Blood Cancer J. 2018 Jun 12;8(6):60. doi: 10.1038/s41408-018-0089-0.

13.

Concise Review: Age-Related Clonal Hematopoiesis: Stem Cells Tempting the Devil.

Busque L, Buscarlet M, Mollica L, Levine RL.

Stem Cells. 2018 Sep;36(9):1287-1294. doi: 10.1002/stem.2845. Epub 2018 Jun 8. Review.

PMID:
29883022
14.

Prevalence of Clonal Hematopoiesis Mutations in Tumor-Only Clinical Genomic Profiling of Solid Tumors.

Ptashkin RN, Mandelker DL, Coombs CC, Bolton K, Yelskaya Z, Hyman DM, Solit DB, Baselga J, Arcila ME, Ladanyi M, Zhang L, Levine RL, Berger MF, Zehir A.

JAMA Oncol. 2018 Nov 1;4(11):1589-1593. doi: 10.1001/jamaoncol.2018.2297.

PMID:
29872864
15.

Identification of Clonal Hematopoiesis Mutations in Solid Tumor Patients Undergoing Unpaired Next-Generation Sequencing Assays.

Coombs CC, Gillis NK, Tan X, Berg JS, Ball M, Balasis ME, Montgomery ND, Bolton KL, Parker JS, Mesa TE, Yoder SJ, Hayward MC, Patel NM, Richards KL, Walko CM, Knepper TC, Soper JT, Weiss J, Grilley-Olson JE, Kim WY, Earp HS 3rd, Levine RL, Papaemmanuil E, Zehir A, Hayes DN, Padron E.

Clin Cancer Res. 2018 Jun 4. doi: 10.1158/1078-0432.CCR-18-1201. [Epub ahead of print]

PMID:
29866652
16.

Dual Targeting of Oncogenic Activation and Inflammatory Signaling Increases Therapeutic Efficacy in Myeloproliferative Neoplasms.

Kleppe M, Koche R, Zou L, van Galen P, Hill CE, Dong L, De Groote S, Papalexi E, Hanasoge Somasundara AV, Cordner K, Keller M, Farnoud N, Medina J, McGovern E, Reyes J, Roberts J, Witkin M, Rapaport F, Teruya-Feldstein J, Qi J, Rampal R, Bernstein BE, Bradner JE, Levine RL.

Cancer Cell. 2018 Apr 9;33(4):785-787. doi: 10.1016/j.ccell.2018.03.024. No abstract available.

17.

Myristoylated methionine sulfoxide reductase A is a late endosomal protein.

Lim JM, Lim JC, Kim G, Levine RL.

J Biol Chem. 2018 May 11;293(19):7355-7366. doi: 10.1074/jbc.RA117.000473. Epub 2018 Mar 28.

PMID:
29593096
18.

LSD1 inhibition exerts its antileukemic effect by recommissioning PU.1- and C/EBPα-dependent enhancers in AML.

Cusan M, Cai SF, Mohammad HP, Krivtsov A, Chramiec A, Loizou E, Witkin MD, Smitheman KN, Tenen DG, Ye M, Will B, Steidl U, Kruger RG, Levine RL, Rienhoff HY Jr, Koche RP, Armstrong SA.

Blood. 2018 Apr 12;131(15):1730-1742. doi: 10.1182/blood-2017-09-807024. Epub 2018 Feb 16.

PMID:
29453291
19.

Jak1 Integrates Cytokine Sensing to Regulate Hematopoietic Stem Cell Function and Stress Hematopoiesis.

Kleppe M, Spitzer MH, Li S, Hill CE, Dong L, Papalexi E, De Groote S, Bowman RL, Keller M, Koppikar P, Rapaport FT, Teruya-Feldstein J, Gandara J, Mason CE, Nolan GP, Levine RL.

Cell Stem Cell. 2018 Feb 1;22(2):277. doi: 10.1016/j.stem.2017.12.018. No abstract available.

PMID:
29395057
20.

Clonal Hematopoiesis and Evolution to Hematopoietic Malignancies.

Bowman RL, Busque L, Levine RL.

Cell Stem Cell. 2018 Feb 1;22(2):157-170. doi: 10.1016/j.stem.2018.01.011. Review.

PMID:
29395053
21.

Isoindole Linkages Provide a Pathway for DOPAL-Mediated Cross-Linking of α-Synuclein.

Werner-Allen JW, Monti S, DuMond JF, Levine RL, Bax A.

Biochemistry. 2018 Mar 6;57(9):1462-1474. doi: 10.1021/acs.biochem.7b01164. Epub 2018 Feb 15.

22.

TRAF6 Mediates Basal Activation of NF-κB Necessary for Hematopoietic Stem Cell Homeostasis.

Fang J, Muto T, Kleppe M, Bolanos LC, Hueneman KM, Walker CS, Sampson L, Wellendorf AM, Chetal K, Choi K, Salomonis N, Choi Y, Zheng Y, Cancelas JA, Levine RL, Starczynowski DT.

Cell Rep. 2018 Jan 30;22(5):1250-1262. doi: 10.1016/j.celrep.2018.01.013.

23.

Even malaria parasites watch their host's diet.

Williamson KC, Levine RL, Miller LH.

Nat Microbiol. 2018 Feb;3(2):130-131. doi: 10.1038/s41564-017-0105-3. No abstract available.

PMID:
29358679
24.

JAK2/IDH-mutant-driven myeloproliferative neoplasm is sensitive to combined targeted inhibition.

McKenney AS, Lau AN, Somasundara AVH, Spitzer B, Intlekofer AM, Ahn J, Shank K, Rapaport FT, Patel MA, Papalexi E, Shih AH, Chiu A, Freinkman E, Akbay EA, Steadman M, Nagaraja R, Yen K, Teruya-Feldstein J, Wong KK, Rampal R, Vander Heiden MG, Thompson CB, Levine RL.

J Clin Invest. 2018 Feb 1;128(2):789-804. doi: 10.1172/JCI94516. Epub 2018 Jan 22.

25.

Methionine in Proteins: It's Not Just for Protein Initiation Anymore.

Lim JM, Kim G, Levine RL.

Neurochem Res. 2018 Jan 11. doi: 10.1007/s11064-017-2460-0. [Epub ahead of print]

PMID:
29327308
26.

Cohesin mutations in myeloid malignancies made simple.

Viny AD, Levine RL.

Curr Opin Hematol. 2018 Mar;25(2):61-66. doi: 10.1097/MOH.0000000000000405.

PMID:
29278534
27.

Cooperative Epigenetic Remodeling by TET2 Loss and NRAS Mutation Drives Myeloid Transformation and MEK Inhibitor Sensitivity.

Kunimoto H, Meydan C, Nazir A, Whitfield J, Shank K, Rapaport F, Maher R, Pronier E, Meyer SC, Garrett-Bakelman FE, Tallman M, Melnick A, Levine RL, Shih AH.

Cancer Cell. 2018 Jan 8;33(1):44-59.e8. doi: 10.1016/j.ccell.2017.11.012. Epub 2017 Dec 21.

PMID:
29275866
28.

Dual Targeting of Oncogenic Activation and Inflammatory Signaling Increases Therapeutic Efficacy in Myeloproliferative Neoplasms.

Kleppe M, Koche R, Zou L, van Galen P, Hill CE, Dong L, De Groote S, Papalexi E, Hanasoge Somasundara AV, Cordner K, Keller M, Farnoud N, Medina J, McGovern E, Reyes J, Roberts J, Witkin M, Rapaport F, Teruya-Feldstein J, Qi J, Rampal R, Bernstein BE, Bradner JE, Levine RL.

Cancer Cell. 2018 Jan 8;33(1):29-43.e7. doi: 10.1016/j.ccell.2017.11.009. Epub 2017 Dec 14. Erratum in: Cancer Cell. 2018 Apr 9;33(4):785-787.

PMID:
29249691
29.

Mediator Kinase Phosphorylation of STAT1 S727 Promotes Growth of Neoplasms With JAK-STAT Activation.

Nitulescu II, Meyer SC, Wen QJ, Crispino JD, Lemieux ME, Levine RL, Pelish HE, Shair MD.

EBioMedicine. 2017 Dec;26:112-125. doi: 10.1016/j.ebiom.2017.11.013. Epub 2017 Nov 21.

30.

Hsp90 inhibition disrupts JAK-STAT signaling and leads to reductions in splenomegaly in patients with myeloproliferative neoplasms.

Hobbs GS, Hanasoge Somasundara AV, Kleppe M, Litvin R, Arcila M, Ahn J, McKenney AS, Knapp K, Ptashkin R, Weinstein H, Heinemann MH, Francis J, Chanel S, Berman E, Mauro M, Tallman MS, Heaney ML, Levine RL, Rampal RK.

Haematologica. 2018 Jan;103(1):e5-e9. doi: 10.3324/haematol.2017.177600. Epub 2017 Oct 19. No abstract available.

31.

Jak1 Integrates Cytokine Sensing to Regulate Hematopoietic Stem Cell Function and Stress Hematopoiesis.

Kleppe M, Spitzer MH, Li S, Hill CE, Dong L, Papalexi E, De Groote S, Bowman RL, Keller M, Koppikar P, Rapaport FT, Teruya-Feldstein J, Gandara J, Mason CE, Nolan GP, Levine RL.

Cell Stem Cell. 2017 Oct 5;21(4):489-501.e7. doi: 10.1016/j.stem.2017.08.011. Epub 2017 Sep 28. Erratum in: Cell Stem Cell. 2018 Feb 1;22(2):277.

32.

Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes.

Coombs CC, Zehir A, Devlin SM, Kishtagari A, Syed A, Jonsson P, Hyman DM, Solit DB, Robson ME, Baselga J, Arcila ME, Ladanyi M, Tallman MS, Levine RL, Berger MF.

Cell Stem Cell. 2017 Sep 7;21(3):374-382.e4. doi: 10.1016/j.stem.2017.07.010. Epub 2017 Aug 10.

33.

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia.

Stein EM, DiNardo CD, Pollyea DA, Fathi AT, Roboz GJ, Altman JK, Stone RM, DeAngelo DJ, Levine RL, Flinn IW, Kantarjian HM, Collins R, Patel MR, Frankel AE, Stein A, Sekeres MA, Swords RT, Medeiros BC, Willekens C, Vyas P, Tosolini A, Xu Q, Knight RD, Yen KE, Agresta S, de Botton S, Tallman MS.

Blood. 2017 Aug 10;130(6):722-731. doi: 10.1182/blood-2017-04-779405. Epub 2017 Jun 6.

34.

Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response.

Amatangelo MD, Quek L, Shih A, Stein EM, Roshal M, David MD, Marteyn B, Farnoud NR, de Botton S, Bernard OA, Wu B, Yen KE, Tallman MS, Papaemmanuil E, Penard-Lacronique V, Thakurta A, Vyas P, Levine RL.

Blood. 2017 Aug 10;130(6):732-741. doi: 10.1182/blood-2017-04-779447. Epub 2017 Jun 6.

35.

Lecithin:Cholesterol Acyltransferase Activation by Sulfhydryl-Reactive Small Molecules: Role of Cysteine-31.

Freeman LA, Demosky SJ Jr, Konaklieva M, Kuskovsky R, Aponte A, Ossoli AF, Gordon SM, Koby RF, Manthei KA, Shen M, Vaisman BL, Shamburek RD, Jadhav A, Calabresi L, Gucek M, Tesmer JJG, Levine RL, Remaley AT.

J Pharmacol Exp Ther. 2017 Aug;362(2):306-318. doi: 10.1124/jpet.117.240457. Epub 2017 Jun 2.

36.

Superoxide is the critical driver of DOPAL autoxidation, lysyl adduct formation, and crosslinking of α-synuclein.

Werner-Allen JW, Levine RL, Bax A.

Biochem Biophys Res Commun. 2017 May 27;487(2):281-286. doi: 10.1016/j.bbrc.2017.04.050. Epub 2017 Apr 12.

37.

Efficacy of ALK5 inhibition in myelofibrosis.

Yue L, Bartenstein M, Zhao W, Ho WT, Han Y, Murdun C, Mailloux AW, Zhang L, Wang X, Budhathoki A, Pradhan K, Rapaport F, Wang H, Shao Z, Ren X, Steidl U, Levine RL, Zhao ZJ, Verma A, Epling-Burnette PK.

JCI Insight. 2017 Apr 6;2(7):e90932. doi: 10.1172/jci.insight.90932.

38.

Pennsylvania State Core Competencies for Education on Opioids and Addiction.

Ashburn MA, Levine RL.

Pain Med. 2017 Oct 1;18(10):1890-1894. doi: 10.1093/pm/pnw348.

PMID:
28339890
39.

Multicolor Flow Cytometry and Multigene Next-Generation Sequencing Are Complementary and Highly Predictive for Relapse in Acute Myeloid Leukemia after Allogeneic Transplantation.

Getta BM, Devlin SM, Levine RL, Arcila ME, Mohanty AS, Zehir A, Tallman MS, Giralt SA, Roshal M.

Biol Blood Marrow Transplant. 2017 Jul;23(7):1064-1071. doi: 10.1016/j.bbmt.2017.03.017. Epub 2017 Mar 15.

40.

TET2 in Normal and Malignant Hematopoiesis.

Bowman RL, Levine RL.

Cold Spring Harb Perspect Med. 2017 Aug 1;7(8). pii: a026518. doi: 10.1101/cshperspect.a026518. Review.

PMID:
28242787
41.

Cardiovascular disease: Commonality with cancer.

Tall AR, Levine RL.

Nature. 2017 Mar 2;543(7643):45-47. doi: 10.1038/nature21505. Epub 2017 Feb 22. No abstract available.

PMID:
28225756
42.

Combination Targeted Therapy to Disrupt Aberrant Oncogenic Signaling and Reverse Epigenetic Dysfunction in IDH2- and TET2-Mutant Acute Myeloid Leukemia.

Shih AH, Meydan C, Shank K, Garrett-Bakelman FE, Ward PS, Intlekofer AM, Nazir A, Stein EM, Knapp K, Glass J, Travins J, Straley K, Gliser C, Mason CE, Yen K, Thompson CB, Melnick A, Levine RL.

Cancer Discov. 2017 May;7(5):494-505. doi: 10.1158/2159-8290.CD-16-1049. Epub 2017 Feb 13.

43.

Mesenchymal Cell Reprogramming in Experimental MPLW515L Mouse Model of Myelofibrosis.

Han Y, Yue L, Wei M, Ren X, Shao Z, Zhang L, Levine RL, Epling-Burnette PK.

PLoS One. 2017 Jan 30;12(1):e0166014. doi: 10.1371/journal.pone.0166014. eCollection 2017.

44.

CD99 is a therapeutic target on disease stem cells in myeloid malignancies.

Chung SS, Eng WS, Hu W, Khalaj M, Garrett-Bakelman FE, Tavakkoli M, Levine RL, Carroll M, Klimek VM, Melnick AM, Park CY.

Sci Transl Med. 2017 Jan 25;9(374). pii: eaaj2025. doi: 10.1126/scitranslmed.aaj2025.

45.

Aid is a key regulator of myeloid/erythroid differentiation and DNA methylation in hematopoietic stem/progenitor cells.

Kunimoto H, McKenney AS, Meydan C, Shank K, Nazir A, Rapaport F, Durham B, Garrett-Bakelman FE, Pronier E, Shih AH, Melnick A, Chaudhuri J, Levine RL.

Blood. 2017 Mar 30;129(13):1779-1790. doi: 10.1182/blood-2016-06-721977. Epub 2017 Jan 11.

46.

Endothelial-specific inhibition of NF-κB enhances functional haematopoiesis.

Poulos MG, Ramalingam P, Gutkin MC, Kleppe M, Ginsberg M, Crowley MJ, Elemento O, Levine RL, Rafii S, Kitajewski J, Greenblatt MB, Shim JH, Butler JM.

Nat Commun. 2016 Dec 21;7:13829. doi: 10.1038/ncomms13829.

47.

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.

Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, Dombret H, Ebert BL, Fenaux P, Larson RA, Levine RL, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz M, Sierra J, Tallman MS, Tien HF, Wei AH, Löwenberg B, Bloomfield CD.

Blood. 2017 Jan 26;129(4):424-447. doi: 10.1182/blood-2016-08-733196. Epub 2016 Nov 28. Review.

48.

An Unexpected Chink in the Transcriptional Armor of Plasmacytoid Dendritic Neoplasms.

Kleppe M, Levine RL.

Cancer Cell. 2016 Nov 14;30(5):659-660. doi: 10.1016/j.ccell.2016.10.016.

49.

DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling.

Guryanova OA, Shank K, Spitzer B, Luciani L, Koche RP, Garrett-Bakelman FE, Ganzel C, Durham BH, Mohanty A, Hoermann G, Rivera SA, Chramiec AG, Pronier E, Bastian L, Keller MD, Tovbin D, Loizou E, Weinstein AR, Gonzalez AR, Lieu YK, Rowe JM, Pastore F, McKenney AS, Krivtsov AV, Sperr WR, Cross JR, Mason CE, Tallman MS, Arcila ME, Abdel-Wahab O, Armstrong SA, Kubicek S, Staber PB, Gönen M, Paietta EM, Melnick AM, Nimer SD, Mukherjee S, Levine RL.

Nat Med. 2016 Dec;22(12):1488-1495. doi: 10.1038/nm.4210. Epub 2016 Nov 14.

50.

Acid ceramidase is upregulated in AML and represents a novel therapeutic target.

Tan SF, Liu X, Fox TE, Barth BM, Sharma A, Turner SD, Awwad A, Dewey A, Doi K, Spitzer B, Shah MV, Morad SA, Desai D, Amin S, Zhu J, Liao J, Yun J, Kester M, Claxton DF, Wang HG, Cabot MC, Schuchman EH, Levine RL, Feith DJ, Loughran TP Jr.

Oncotarget. 2016 Dec 13;7(50):83208-83222. doi: 10.18632/oncotarget.13079.

Supplemental Content

Loading ...
Support Center